Pancreatic cancer test developer Bluestar Genomics has raised $70m from investors including Pathology Asia Holdings.

York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.

Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.

Vanderbilt’s Center for Technology Transfer and Commercialization generated nine new companies in 2020 and licensed a significant number of covid-related technologies.

Short-term accommodation provider Cohabs secured more than $70m in a round led by AG Real Estate, while Stampli, Impress and Tarana Wireless each raised $50m.

Weizmann Institute of Science participated in a series B round for its spinout that was originally known as OnSight Medical.

The health data analytics provider counts Johnson & Johnson, McKesson, Amgen, Sanofi, UCB Pharma and Blue Cross Blue Shield of New Jersey as earlier investors.

Human resources software provider Legion and edge cloud services provider Zenlayer each received $50m while Intel is exiting Sedona Systems in a $100m acquisition.

Bayer, Hitachi, Samsung, Sony and Unilever participated in a series C round for the healthcare monitoring technology provider valuing it near to $1bn.

Appia Bio has emerged from stealth with $52m in series A financing to commercialise cancer treatments based on research at UCLA.